Ipca Laboratories Ltd
Ipca Laboratories Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
The short version
Europe growth impacted by one specific product; excluding it, other product sales and margins are strong; registrations in Germany and expanding European footprint expected to drive future growth. Stand-alone EBITDA margin improved by ~2.57% from 22.89% (Q2 FY25) to 25.46% (Q2 FY26), with further margin improvement expected in H2 FY26. - Consolidated EBITDA margin increased by ~2.58% from 19.1% (Q2 FY25) to 21.68% (Q2 FY26), with guidance for better-than-20% margin in H2 FY26. - Sales force expansion stabilized; around 400-500 additional reps annually for next 2-3 years, indicating steady growth support. - R&D spending increased to ~4% of turnover, building a strong pipeline for future growth. - U.S.
From Ipca Laboratories Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Europe growth impacted by one specific product; excluding it, other product sales and margins are strong; registrations in Germany and expanding European footprint expected to drive future growth.
- Started filing Unichem dossiers in Europe to increase product basket and participation in tenders.
- Domestic market growth expected to be higher than overall market; addressing underperforming therapies like cardiac, showing positive results.
- Growth moderation expected in domestic market, but GLP (Goods and Logistics Provider) opportunity seen as a significant growth trigger.
- API business projected to grow around 14-15% for the current financial year; Q2 saw a 28% increase in API revenue.
2 more points from Ipca Laboratories Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Ipca Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current capacity allows development of around 5 to 6 new APIs, focusing on formulation side.
- API development beyond this number is limited; outsourcing considered if API cost is low or generic.
- Expansion on the field force continues but controlled: around 7,000 medical reps currently, with an addition of 400-500 people annually expected for next 2-3 years.
- Addition of new business divisions like cosmetic dermatology and Flexicare (pain management) as strategic growth areas; the Flexicare division is currently incurring losses but expected to scale.
2 more points from Ipca Laboratories Ltd's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Ipca Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Ipca Laboratories Ltd said on order book & pipeline — free account, 30 seconds.
Ipca Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹2.4K Cr, net profit ₹364 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Ipca Laboratories Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare Ltd (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Ipca Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Ipca Laboratories Ltd Q2 FY26 results?
Europe growth impacted by one specific product; excluding it, other product sales and margins are strong; registrations in Germany and expanding European footprint expected to drive future growth. Stand-alone EBITDA margin improved by ~2.57% from 22.89% (Q2 FY25) to 25.46% (Q2 FY26), with further margin improvement expected in H2 FY26. - Consolidated EBITDA margin increased by ~2.58% from 19.1% (Q2 FY25) to 21.68% (Q2 FY26), with guidance for better-than-20% margin in H2 FY26. - Sales force expansion stabilized; around 400-500 additional reps annually for next 2-3 years, indicating steady growth support. - R&D spending increased to ~4% of turnover, building a strong pipeline for future growth. - U.S.
What is Ipca Laboratories Ltd share price analysis?
Ipca Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 33.9 with a market cap of ₹46,494 Cr. Investors should review the full earnings analysis for detailed insights.
Is Ipca Laboratories Ltd planning capital expenditure?
Current capacity allows development of around 5 to 6 new APIs, focusing on formulation side.
Keep Ipca Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.